Issue 47, October 20, 2023
America faces daunting and complex healthcare challenges that include and go beyond the current pandemic. In myriad ways, innovative healthcare companies are developing solutions to improve access to care, battle disease, strengthen population health, and meet the needs of underserved communities. This newsletter will offer examples of Healthcare Leadership Council members answering the call. |
|
|
HLC/Confidentiality Coalition Hill Briefing
Opportunities for Artificial Intelligence within Healthcare As development and utilization of artificial intelligence increases, healthcare stakeholders are invested in shaping how it can improve the lives of patients. Two panels will discuss how their organizations have approached the development and use of artificial intelligence and will provide recommendations for guardrails to ensure integrity, privacy and security. Provider Panel 1: Marshfield Clinic
NY Presbyterian (invited) Mayo Clinic (invited) Industry Panel 2: EMD Group Oracle Premier When: November 2, 2023 12:00 p.m - 1:00 p.m. ET
Where: Rayburn HOB Room 2045
RSVP to kfernandez@hlc.org HLC Webinar Redefining American Healthcare: The Boots on the Ground
A panel of recent recipients of the Healthcare Leadership Council's Redefining American Healthcare Award will highlight how their work has helped change the lives of underserved populations. They will also address barriers faced and recommendations for a better future.
Organizations: - Palmetto Care Connections
- TESCO Specialty Vehicles
- African American Infant and Maternal Mortality (AAIMM) Prevention Initiative
- Change Matrix (Colorado Equity Compass)
When: November 8 at 2pm ET |
| Wellvana, AdventHealth Collaborate to Improve Clinical Outcomes, Access to Care
Wellvana, a value-based care enablement company for primary care physicians, specialists, health systems, and payors has announced its exclusive partnership with AdventHealth's Primary Care Network in Florida to improve clinical outcomes and extent access to whole-person care for its primary care patients. AdventHealth is one of the nation's largest faith-based health systems. Both Wellvana and AdventHealth are members of the Healthcare Leadership Council.
The Wellvana approach empowers primary care physicians to focus on high-quality preventive care as they transition from fee-for-service care delivery to full risk-based contracting where the system takes financial responsibility for each patient cared for, which incentivizes coordinated care to improve outcomes and reduce the total cost of care per patient. Wellvana will devote a clinical support team to AdventHealth's primary care clinics to increase patient access to RNs, social workers and trained pharmacists, as well as provide timely scheduling and care gap closure coordination.
Kyle Wailes, Wellvana Chief Executive Officer said, "Half measures in value-based care have held back progress for hospitals. But AdventHealth has boldly drawn a line in the sand - their providers and patients deserve more. And we're honored they chose Wellvana as their partner. AdventHealth's culture is steeped in integrity and relentless stewardship, which aligns to Wellvana's core values and high-touch, on-the-ground approach to help high-performing physicians." |
Genentech Releases Data Showing Treatment's Success in Preventing Multiple Sclerosis Disease Progression
Genentech, a member of the Healthcare Leadership Council, has announced new clinical and real-world data demonstrating that its treatment Ocrevus is continuing to transform care for people living with relapsing or primary progressive multiple sclerosis. According to the director of the Weill Institute for Neurosciences at the University of California, San Francisco, the data signifies that people with both relapsing multiple sclerosis and primary progressive multiple sclerosis "have more years to spend their days living independently without the need for walking aids or wheelchairs."
After 10 years of continuous Ocrevus treatment, 77% of patients with relapsing multiple sclerosis were free from disability progression based on 48-week confirmed disability progressive events and 92% of patients were still walking unassisted. In patients with primary progressive multiple sclerosis, 36% were free from disability progression and 80% of those treated continuously with Ocrevus over 10 years were still able to walk. Also, on an issue important to women of child-bearing age with multiple sclerosis, safety data do not suggest an increased risk of adverse pregnancy or infant outcomes in women with MS treated with the drug.
Levi Garraway, M.D., Ph.D., Genetech's chief medical officer and head of Global Product Development said, "Some women affected by MS may be thinking about starting a family, so it is important to understand how their treatment prior to pregnancy may impact them and their unborn child. With more than 300,000 people treated globally and 30 ongoing trials, we continue to accrue robust evidence for how Ocrevus may benefit many underrepresented groups including pregnant women." |
|
|
|